Adverse Events in the Treatment of Cancer Patients: Neurotoxicity, Vasculitis, Encephalitis, and Aseptic Meningitis
Abstract
Adverse events affecting the central and peripheral nervous systems of associated with antitumor therapy, including radiation therapy, immunotherapy, and chemotherapy, remain a complex diagnostic and clinical challenge. Magnetic resonance imaging (MRI) is the main tool for assessing central neurotoxicity, allowing prevention of tumor progression, infectious and drug-induced changes, and vascular lesions. This article reviews current data on the pathogenesis, clinical manifestations, and typical MRI patterns of the main cerebral complications of cancer treatment.
Keywords
About the Authors
S. G. Gvindzhiia
Scientific Research Institute – Ochapovsky Regional Clinical Hospital No. 1; Kuban State Medical University
Russian Federation
Russian Federation
Elena I. Zyablova, Dr. Sci. (Med.), Associate Professor Head of the Department of Radiation Diagnostics No. 2; Head of the X-ray Department; Chief Freelance Radiologist of the Ministry of Health of the Krasnodar Region
167 1 Maya St., Krasnodar, 350086
E. Yu. Krivitskaya
Scientific Research Institute – Ochapovsky Regional Clinical Hospital No. 1; Kuban State Medical University
Russian Federation
Russian Federation
Elena Yu. Krivitskaya, Radiologist X-ray Department; Assistant, Department of Radiation Diagnostics No. 2
Krasnodar
E. I. Zyablova
Scientific Research Institute – Ochapovsky Regional Clinical Hospital No. 1; Kuban State Medical University
Russian Federation
Russian Federation
Saria G. Gvindzhiia, Radiologist, X-ray Department; Assistant Professor, Department of Radiation Diagnostics No. 2
Krasnodar
References
1. Зяблова Е.И. Визуализация побочных эффектов противоопухолевой терапии / Е.И. Зяблова. Краснодар: Кубанский государственный медицинский университет, 2025. – 156 с. – EDN YCEOIW.
2. Lesley A Colvin. Chemotherapy-induced peripheral neuropathy (CIPN): where are we now? 2019 May; 160(Suppl 1): S1–S10. doi: 10.1097/j.pain.0000000000001540. PMCID: PMC6499732. EMSID: EMS81981. PMID: 31008843.
3. Jeremy H. Rees. The EBMT/EHA CAR-T Cell Handbook, Chapter 27: Management of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS). February 7, 2022. URL: https://www.ncbi.nlm.nih.gov/books/NBK584157/.
4. Pozzessere [et al.]. Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors and CAR-T Cell Therapy / C. // A Comprehensive Imaging-Based Review. Cancers (Basel). 2024 Jul 19. No 16 (14). P. 2585. DOI: 10.3390/cancers16142585; PMID: 39061225; PMCID: PMC11274393.
5. Stephen Klaus, Raluca Stanila. Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) & New Onset Seizures with Overlapping MRI Sequelae. URL: https://aesnet.org/abstractslisting/immune-effector-cell-associated-neurotoxicity-syndromeicans-and-new-onset-seizures-with-overlapping-mri-sequelae.
6. Gaillard F, Immune effector cell-associated neurotoxicity syndrome (ICANS). Case study, https://doi.org/10.53347/rID163107.
7. Gimber LH, Garland L, Krupinski EA, Chadaz TS, Schwenk M, Najafi B, Taljanovic MS. Diffusion Tensor Imaging of the Ankle as a Possible Predictor of Chemotherapy Induced Peripheral Neuropathy: Pilot Study. Curr Probl Diagn Radiol. 2019 MarApr;48(2):121-126. doi: 10.1067/j.cpradiol.2017.12.012. Epub 2018 Jan 6. PMID: 29397266.
8. Buckley MW, Balaji Warner A, Brahmer J, Cappelli LC, Sharfman WH, Fuchs E, Kang H, Forde PM, Gladstone DE, Ambinder R, Kelly RJ, Lipson EJ, Gojo I, Lee EJ, Johnson TP, Saidha S, Llinas R, Ostrow LW, Naidoo J, Probasco JC. Immune-related encephalitis after immune checkpoint inhibitor therapy. Oncologist. 2025 Jan 17;30(1):oyae186. doi: 10.1093/oncolo/oyae186. PMID: 39066587; PMCID: PMC11783331.
9. Velasco R, Villagrán M, Jové M, Simó M, Vilariño N, Alemany M, Palmero R, Martínez-Villacampa MM, Nadal E, Bruna J. Encephalitis Induced by Immune Checkpoint Inhibitors: A Systematic Review. JAMA Neurol. 2021 Jul 1;78(7):864-873. doi: 10.1001/jamaneurol.2021.0249. PMID: 33720308.
10. Zhao Z, Zhang C, Zhou L, Dong P, Shi L. Immune Checkpoint Inhibitors and Neurotoxicity. Curr Neuropharmacol. 2021;19(8):1246-1263. doi: 10.2174/1570159X196662012301512 24. PMID: 33380303; PMCID: PMC8719293.
11. Melissa Yelehe-Okouma, Julie Czmil-Garon, Elise Pape, Nadine Petitpain, Pierre Gillet. Drug-induced aseptic meningitis: a mini-review. 24 January 2018.
12. Nannini S, Koshenkova L, Baloglu S, Chaussemy D, Noël G, Schott R. Immune-related aseptic meningitis and strategies to manage immune checkpoint inhibitor therapy: a systematic review. J Neurooncol. 2022 May;157(3):533-550. doi: 10.1007/s11060-022-03997-7. Epub 2022 Apr 13. PMID: 35416575; PMCID: PMC9458695.
13. Feng J, Ross L, Ontaneda D. Pembrolizumab-Induced CNS Vasculitis: Neurologic Adverse Events Due to Checkpoint Inhibitors. Neurol Clin Pract. 2021 Feb;11(1):e30-e32. doi: 10.1212/CPJ.0000000000000768. PMID: 33968488; PMCID: PMC8101305.
14. Crout TM, Lennep DS, Kishore S, Majithia V. Systemic Vasculitis Associated With Immune Check Point Inhibition: Analysis and Review. Curr Rheumatol Rep. 2019 May 21;21(6):28. doi: 10.1007/s11926-019-0828-7. PMID: 31115712.
Review
For citations:
Gvindzhiia S.G., Krivitskaya E.Yu., Zyablova E.I. Adverse Events in the Treatment of Cancer Patients: Neurotoxicity, Vasculitis, Encephalitis, and Aseptic Meningitis. Innovative Medicine of Kuban. 2026;11(1-1):19-26. (In Russ.)
Views:
146
JATS XML
Email this article 
